Tandem Diabetes Care (NASDAQ:TNDM) shareholders have endured a 69% loss from investing in the stock three years ago

While it may not be enough for some shareholders, we think it is good to see the Tandem Diabetes Care, Inc. (NASDAQ:TNDM) share price up 18% in a single quarter. But that is small recompense for the exasperating returns over three years. Indeed, the share price is down a tragic 69% in the last three years. So it's good to see it climbing back up. The rise has some hopeful, but turnarounds are often precarious.

Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.

Check out our latest analysis for Tandem Diabetes Care

Because Tandem Diabetes Care made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally hope to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

Over three years, Tandem Diabetes Care grew revenue at 4.7% per year. Given it's losing money in pursuit of growth, we are not really impressed with that. This uninspiring revenue growth has no doubt helped send the share price lower; it dropped 19% during the period. When a stock falls hard like this, some investors like to add the company to a watchlist (in case the business recovers, longer term). Keep in mind it isn't unusual for good businesses to have a tough time or a couple of uninspiring years.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

Tandem Diabetes Care is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. If you are thinking of buying or selling Tandem Diabetes Care stock, you should check out this free report showing analyst consensus estimates for future profits.

A Different Perspective

It's good to see that Tandem Diabetes Care has rewarded shareholders with a total shareholder return of 55% in the last twelve months. Notably the five-year annualised TSR loss of 10% per year compares very unfavourably with the recent share price performance. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. It's always interesting to track share price performance over the longer term. But to understand Tandem Diabetes Care better, we need to consider many other factors. Take risks, for example - Tandem Diabetes Care has 2 warning signs we think you should be aware of.

For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.